SCHEMBL1640740

SCHEMBL1640740

O=C(NC1CCCC1)c1cn(Cc2ccccc2)c(=O)cc1O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 11/20 0.63
CNR2 P34972 11/20 0.63
BRD4 O60885 2/20 0.55
ALDH1A1 P00352 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
NPC1 O15118 1/20 0.52
MAPT P10636 1/20 0.52
TRIM24 O15164 1/20 0.52
BRD1 O95696 1/20 0.52
CCL2 P13500 1/20 0.52
TAF1 P21675 1/20 0.52
BRD2 P25440 1/20 0.52
SMARCA2 P51531 1/20 0.52
SMARCA4 P51532 1/20 0.52
BRPF1 P55201 1/20 0.52
EP300 Q09472 1/20 0.52
BPTF Q12830 1/20 0.52
CACNA1C Q13936 1/20 0.52
BRD3 Q15059 1/20 0.52
BRDT Q58F21 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1641067 0.99 CNR1 (0.65) CNR1CNR2BRD4ALDH1A1SMN1; SMN2
SCHEMBL1642259 0.88 CNR1 (0.60) CNR1CNR2
SCHEMBL1642081 0.86 ALDH1A1 (0.53) CNR1CNR2ALDH1A1NPC1MAPT
SCHEMBL1642163 0.85 CNR1 (0.52) CNR1CNR2
SCHEMBL1642256 0.81 MEN1 (0.49) CNR1CNR2ALDH1A1NPC1MAPT
SCHEMBL1640573 0.80 BRD4 (0.65) BRD4ALDH1A1SMN1; SMN2MAPTTRIM24
SCHEMBL1641827 0.80 BRD4 (0.57) BRD4MAPTBRD2BRD3BRDT
SCHEMBL1641226 0.80 BRD4 (0.53) CNR1CNR2BRD4ALDH1A1SMN1; SMN2
SCHEMBL1640326 0.79 HSP90AA1 (0.58) CNR2BRD4ALDH1A1SMN1; SMN2MAPT
SCHEMBL1642053 0.79 MAPT (0.59) BRD4ALDH1A1SMN1; SMN2MAPTBRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN2, EGLN3 CNR1 2636/4885CNR2 2738/4885BRD4 3195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.